GeoVax Labs (NASDAQ:GOVX) Releases Quarterly Earnings Results, Beats Expectations By $0.49 EPS

GeoVax Labs (NASDAQ:GOVX) released its quarterly earnings data on Thursday. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.49, Zacks reports. The business had revenue of $3.00 million during the quarter, compared to the consensus estimate of $2.38 million.

GeoVax Labs Price Performance

GOVX stock opened at $1.27 on Friday. The business’s 50-day moving average is $1.69 and its two-hundred day moving average is $2.16. GeoVax Labs has a fifty-two week low of $1.09 and a fifty-two week high of $11.18.

Analyst Ratings Changes

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $18.00 price target on shares of GeoVax Labs in a report on Thursday, February 27th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, GeoVax Labs currently has a consensus rating of “Buy” and an average target price of $14.20.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.